Alias :D ulaglutide – solution in PBS/ dulaglutide

CAS No.:923950-08-7

Company No. :GT-F002

Sequence: H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Glu-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gl y-Gly-OH

Molecular formula: C149H221N37O49

Molecular weight: 3314.62


Dulaglutide CAS NO. 923950-08-7.jpg

Technical indicators:

Appearance White powder
The purity (HPLC) was ≥95.0%

The single heterozygosity was less than 2.0%

Acetic acid content ranged from 5.0% to 12.0%

The moisture content was ≤10.0%

The peptide content was ≥80.0%

Packing and Shipping:

Low temperature, vacuum packing, accurate to milligram upon request.

Product Description:

Durraglutide is a new long-acting GLP-1R agonist, which is derived from the fusion of two DPP-4 inhibitory GLP-1 analogues and human immunoglobulin heavy chain IgG4-Fc fragment. Its activity is similar to that of endogenous GLP-1 in clinical manifestations, with a half-life of 5 days, and can effectively delay renal clearance. The FDA approved dulaglutide for subcutaneous injection in September 2014. The European Commission approved dulaglutide for subcutaneous injection in Europe in December 2014.

Storage: Freeze dried at -20℃ and stored away from light

Remark: For research purposes only, not for human subjects

Post time: Oct-13-2023